OTC Markets OTCPK - Delayed Quote USD

Revive Therapeutics Ltd. (RVVTF)

0.0180

-0.0002

(-1.10%)

At close: May 14 at 4:00:00 PM EDT

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure. This study is conducted in partnership with Defence R&D Canada – Suffield Research Centre (“DRDC”

GlobeNewswire 2 days ago

RVVTF
-1.10%
Revive Therapeutics Announces Proposed Shares for Debt Transaction

TORONTO, April 21, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, announces that it is proposing to settle an aggregate of $150,000 in payables to arm’s length parties through the issuance of up to 6,000,000 common shares, at a proposed issue price of $0.025 per sha

GlobeNewswire 23 days ago

RVVTF
-1.10%
Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a clinical site initiation, an FDA authorization and an analyst initiation. CLEARMIND INITIATES U.S. SITE FOR CMND-100 TRIAL: Clearmind Medicine (CMND) announced Thursday that it has initiated its Phase I/IIa clinical trial at its first U.S. clinical site, the Johns Hopkins University School of Medicine. The first-in-human clinical trial will investigate the safety, tolerability and

TipRanks last month

RVVTF
-1.10%

AGNPF

ATAI
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment

TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, announced today that it has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute. The researcher aims to investigate Bucillamine’s potential as a cancer treatment,

GlobeNewswire last month

RVVTF
-1.10%
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that further to its press release dated March 3, 2025, it has entered into an asset purchase agreement (the “Agreement”) dated March 31, 2025 with DiagnaMed Holdings Corp. (CSE:

GlobeNewswire last month

DGNMF

RVVTF
-1.10%
Revive Therapeutics Announces Results of Annual Shareholder Meeting

TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce the voting results for its annual and special meeting of shareholders (the “Meeting”) that was held on Tuesday, March 18, 2025. At the Meeting, shareholders elected the followin

GlobeNewswire last month

RVVTF
-1.10%
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”), dated February 28, 2025, to acquire the full rights to DiagnaMed Holdings Corp.’s (CSE: DMED) (OTCQB: DGNMF)

GlobeNewswire 2 months ago

RVVTF
-1.10%

DGNMF
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today an update on its research and development focus on Bucillamine. Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, has a well-known safety profile and is prescribed i

GlobeNewswire 3 months ago

RVVTF
-1.10%
Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

TORONTO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, medical countermeasures and rare disorders, today announced the publication of a scientific article demonstrating the potential of psilocybin as a novel therapeutic approach in stroke. The publication, entitled, “Neuroprotective effects of psiloc

GlobeNewswire 5 months ago

RVVTF
-1.10%

PHRRF
Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

TORONTO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures, announced today its strategic focus on dedicating its resources to advancing the clinical development of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties. The Company has decided n

GlobeNewswire 7 months ago

RVVTF
-1.10%
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections

TORONTO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the research study evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R&D Canada – Suffield Research Cent

GlobeNewswire 8 months ago

RVVTF
-1.10%
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID

TORONTO, June 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the Type C meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical stud

GlobeNewswire 10 months ago

RVVTF
-1.10%
Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product

TORONTO, June 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today an update on the meeting written responses received by the Company from the U.S. Food & Drug Administration (“FDA”) of the Revive LC POC Lateral Flow Test Kit (the “Prod

GlobeNewswire 10 months ago

RVVTF
-1.10%

Performance Overview

Return	RVVTF	S&P/TSX Composite index (^GSPTSE)
YTD	+157.14%	+4.35%
1-Year	-14.29%	+15.51%
3-Year	-89.77%	+27.82%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Revive Therapeutics Ltd. (RVVTF)

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

Revive Therapeutics Announces Proposed Shares for Debt Transaction

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial

Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment

Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

Revive Therapeutics Announces Results of Annual Shareholder Meeting

Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections

Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID

Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product

Performance Overview